Physician profile
Jonathan Moreira
NPI 1336371590
$28,812.44
in general payments reported to CMS, 2019-2025
15 companies · $24.08 in 2025
The $24.08 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $113 · 2021: $14.13 · 2022: $3,612 · 2023: $4,831 · 2024: $2,289 · 2025: $24.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,880 · Food and Beverage: $243 · Travel and Lodging: $21.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,880.00 |
| Food and Beverage | $242.88 |
| Travel and Lodging | $21.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13,800.00 | 2019-2022 | |
| Kite Pharma, INC. | $7,031.32 | 2023-2024 | Yescarta |
| Jazz Pharmaceuticals INC. | $4,606.95 | 2019 | |
| Incyte Corporation | $3,121.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.19 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.89 | 2024 | |
| Abbvie INC. | $27.94 | 2024 | |
| Astellas Pharma US INC | $24.08 | 2025 | Cresemba |
| Regeneron Healthcare Solutions, INC. | $14.13 | 2021 | |
| Acrotech Biopharma INC. | $11.97 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Moreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.